NCIC CLINICAL TRIALS GROUP

GASTROINTESTINAL DISEASE SITE SPRING 2006

COLON DISEASE ORIENTED GROUP - CDOG

AGENDA

OPEN SESSION
Venue: Hilton Montreal Bonaventure Hotel, Montreal
Room: Salon Verriere
Date: Saturday, April 29th, 2006
Time: 8:30 am – 10:00 am
Chair: Dr. Derek Jonker

8:30 am WELCOME AND INTRODUCTION
Dr D. Jonker

8:35 am UPDATE OF RECENTLY CLOSED TRIALS

CO.17: A PHASE III Randomized Multicenter Study of Erbitux® (Cetuximab) and Best Supportive Care vs. Best Supportive Care in patients with Pretreated, Metastatic, EGFR-Positive Colorectal Carcinoma

CO.19: A Phase III Randomized Double-Blind Placebo-Controlled Trial of FOLFOX with or without PTK 787 after Curative Resection for Patients with Stage III Colon Cancer

8:40 am UPDATE OF ACTIVE TRIALS

CRC.2 (N0147): A Randomized Phase III Trial of Irinotecan (CPT-11) and/or Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer.

IND.171: A Phase I, Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination with Standard Chemotherapy Regimens (CT) in Patients with Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer

IND.175: A Phase I, Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination with Standard Chemotherapy Regimens (CT) in Patients with Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer

8:50 am UPDATE OF TRIALS PENDING ACTIVATION

CRC.3 (ECOG 5202): A Randomized Phase III Study Comparing 5-FU Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers.

CO.18: A Phase II Study of AZD2171 and Capecitabine versus Capecitabine Alone as 1st Line Therapy in Patients with Metastatic Colorectal Cancer
CO.20: A Phase III Randomized Study of BMS582664 and Cetuximab (Erbitux™) versus Cetuximab in Patients with Pretreated Metastatic Colorectal Carcinoma

9:05 am  UPDATE OF OTHER CTSU TRIALS

NSABP CO.8: A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) every Two Weeks with Bevacizumab to the Same Regimen without Bevacizumab for the Treatment of Patients with Resected Stages II and III Carcinoma of the Colon

CALGB 80405: A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU / Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

SWOG S0600 iBet (Intergroup Bevacizumab Continuation Trial): Patients with mCRC who have failed first-line treatment with oxaliplatin plus bevacizumab. The trial will compare FOLFIRI/irinotecan plus cetuximab with FOLFIRI/irinotecan plus cetuximab and bevacizumab.

9:15 am  NEW PROPOSALS FOR CONSIDERATION

Phase II Camptosar/Oxaliplatin/Xeloda (COX) ± Bevacizumab:  Dr J. Maroun

Phase I Colon:  Dr Ralph Wong

Liver Resection Studies:  Dr S. Gallinger

9:35 pm  DISCUSSION  Dr D. Jonker

9:55 pm  CLOSING REMARKS & ADJOURNMENT  Dr D. Jonker